Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

Ravulizumab, a novel long‐acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non‐inferior to eculizumab for all efficacy outcomes in two randomised, open‐label, phase 3 trials in C5 inhibitor‐naïve (Study 301) and eculizumab‐experienced (Study 302) adult patients with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: Peffault de Latour, Régis, Brodsky, Robert A., Ortiz, Stephan, Risitano, Antonio M., Jang, Jun H., Hillmen, Peter, Kulagin, Alexander D., Kulasekararaj, Austin G., Rottinghaus, Scott T., Aguzzi, Rasha, Gao, Xiang, Wells, Richard A., Szer, Jeff
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Red cells and Iron
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7687070/
https://ncbi.nlm.nih.gov/pubmed/32449174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16711
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars